Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.53 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | WNK1 | Q9H4A3 | 2/20 | 0.49 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.48 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3098587 | 0.97 | VCAM1 (0.61) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL10389384 | 0.96 | TP53 (0.61) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL12549754 | 0.85 | ALDH1A1 (0.56) | VCAM1SMN1; SMN2MAPK1NPBWR1MCHR1 | |
| SCHEMBL516882 | 0.82 | VCAM1 (0.53) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL516883 | 0.82 | VCAM1 (0.53) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL12550128 | 0.81 | VCAM1 (0.52) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL9796179 | 0.80 | ALDH1A1 (0.68) | SMN1; SMN2MAPK1MEN1KMT2ALMNA | |
| SCHEMBL516635 | 0.79 | VCAM1 (0.52) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL516636 | 0.79 | VCAM1 (0.52) | VCAM1SMN1; SMN2MAPK1TP53PKM | |
| SCHEMBL3093045 | 0.78 | WNK1 (0.56) | SMN1; SMN2MAPK1TP53PKMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2010-08-26 | — | — | US | disclosed |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216801-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | VCAM1 1343/4885SMN1; SMN2 2523/4885MAPK1 1490/4885 |
| US-20090203692-A1 | NOVEL CHEMICAL COMPOUNDS | HIPK3, HIPK1, HIPK4 | VCAM1 1525/4885SMN1; SMN2 2437/4885MAPK1 1625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.